Startup scores Amgen exec
PBS Biotech, a Camarillo-based startup focused on biotechnology equipment founded by a former Amgen scientist, has added major firepower to its advisory board with a key former Amgen executive. George Morrow oversaw global operations for Thousand Oaks-based Amgen, the world’s largest biotech firm, for eight years before retiring last year. He came to Amgen after Read More →
Read More →Amgen CEO to step down
Kevin Sharer, chairman and CEO of Amgen, is set to retire in May, the Thousand Oaks-based company said on Dec. 15. Current president and chief operating officer Robert Bradway will become the company’s new CEO. Sharer led Amgen, the largest private-sector employer in Ventura County, for 11 years. He oversaw the company’s transition from the Read More →
Read More →Amgen wraps up buyback auction
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”08-06-2011″ enddate=”08-12-2011″ width=”300″ height=”245″] Amgen, based in Thousand Oaks, expects to repurchase 9.6 percent of its outstanding shares at a price of $60 per share after asking shareholders to name their price in a buyback auction. The biotech giant and major Ventura County employer said Dec. 8 it had completed Read More →
Read More →Amgen kicks off debt offering
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”30-05-2011″ enddate=”30-11-2011″ width=”300″ height=”245″] Amgen has priced more than $1 billion in debt offerings as it loads up on cash for its massive stock buyback and dividend program. The company said it had priced $550 million of senior notes due 2018 and an additional $475 million in senior notes due Read More →
Read More →Amgen is Big Pharma’s newest player
Nov. 7, 2011 should be remembered as the date when Amgen resigned its charter membership in the biotech growth club and joined Big Pharma.
Read More →Amgen launches $5B buyback
Amgen said Nov. 7 that it plans to buy back $5 billion of its shares as part of a push to return profit to stockholders. Shares of the Thousand Oaks-based drugmaker jumped 4.5 percent in morning trading. Moody’s Investors Service and Fitch Ratings lowered their ratings on Amgen debt after the announcement because the biotech Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
